InnoCare Pharma Limited provided earnings guidance for the year ended 31 December 2023. Based on a preliminary estimate by the finance department, the net loss attributable to owners of the parent company in 2023 is expected to be approximately RMB 656 million, representing a decrease in loss of approximately 26% as compared with the corresponding period of the previous year. The net loss after excluding non-recurring gains or losses attributable to owners of the parent company was approximately RMB 654 million, representing a decrease of approximately 32% as compared with the corresponding period of the previous year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.13 HKD | -0.58% | +0.98% | -25.54% |
05-14 | Innocare Pharma Posts Q1 Loss | MT |
05-13 | InnoCare Logs Loss in Q1 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.54% | 1.3B | |
+7.52% | 111B | |
+11.38% | 106B | |
-12.64% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.58% | 16.81B | |
+37.41% | 12.54B | |
-23.95% | 8.09B |
- Stock Market
- Equities
- 9969 Stock
- News InnoCare Pharma Limited
- InnoCare Pharma Limited Provides Earnings Guidance for the Year Ended 31 December 2023